# 18F-mFBG Imaging for Myocardial Sympathetic Innervation

> **NCT06965621** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)** · enrollment: 20 (estimated)

## Conditions studied

- Heart Failure
- Ischemic Cardiomyopathy
- ICD Patients

## Interventions

- **DRUG:** 18F-metaFluorobenzylguanidine
- **DRUG:** Rubidium-82

## Key facts

- **NCT ID:** NCT06965621
- **Lead sponsor:** Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-28
- **Primary completion:** 2026-10-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06965621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06965621, "18F-mFBG Imaging for Myocardial Sympathetic Innervation". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06965621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*